Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.78 |
| ▸ | HPGD | P15428 | 3/20 | 0.78 |
| ▸ | HTR1A | P08908 | 2/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 1/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644144 | 1.00 | KDM4E (0.78) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL25308221 | 0.90 | KDM4E (0.64) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL9247970 | 0.90 | KDM4E (0.63) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL9247967 | 0.90 | KDM4E (0.63) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| Sinapic Acid Methyl Ether SCHEMBL207442 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| Sinapic Acid Methyl Ether SCHEMBL207441 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL4651382 | 0.87 | PKM (0.78) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL5573125 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| SCHEMBL5573123 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1HPGDHTR1AHSD17B10 | |
| Sinapic Acid Methyl Ether SCHEMBL9848210 | 0.86 | KDM4E (0.96) | KDM4EALDH1A1HPGDHTR1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61093171-A | — | — | None | — | — | JP | disclosed |
| JP-61072773-A | — | — | None | — | — | JP | disclosed |
| CN-115611840-B | Cold winter honey element and preparation method and application thereof | 广西梧州甜蜜家蜂业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023131362-A1 | PHENYLPROPANOID DERIVATIVES | USTAV EXPERIMENTALNI BOTANIKY AV ČR, V. V. I. (CZ) | 2023-07-13 | — | — | WO | disclosed |
| EP-1057815-B1 | CYCLIC AMIDE COMPOUNDS | KOWA CO (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-6645957-B2 | Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis | KOWA CO., LTD. (JP) | 2003-11-11 | — | — | US | disclosed |
| US-20030096828-A1 | Cyclic amide compound | KOWA CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| US-6448242-B1 | COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS | KOWA CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| EP-1057815-A1 | CYCLIC AMIDE COMPOUNDS | Kowa Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0236227-B1 | NITRATE DERIVATIVES AND THEIR USE AS VASODILATORS | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1989-12-13 | — | — | EP | disclosed |
| US-4792553-A | TREATMENT OF CARDIOVASCULAR AND CEREBROVASCULAR DISORDERS | TERUMO KABUSHIKI KAISHA (JP) | 1988-12-20 | — | — | US | disclosed |
| EP-0175331-B1 | PIPERAZINE DERIVATIVES | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1988-11-17 | — | — | EP | disclosed |
| US-4780560-A | Nitrate derivatives and vasodilators containing the same | TERUMO CORPORATION (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0236227-A1 | Nitrate derivatives and their use as vasodilators | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4673684-A | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO CORPORATION (JP) | 1987-06-16 | — | — | US | disclosed |
| US-4656172-A | CONTROLLING OR PREVENTING CEREBRAL, CORONARY OR PERIPHIPHERAL VASCULAR DISORDER | TERUMO KABUSHIKI KAISHA (JP) | 1987-04-07 | — | — | US | disclosed |
| JP-S6193171-A | HOMOPIPERAZINE DERIVATIVE AND VASODILATOR CONTAINING SAME | TERUMO CORP | 1986-05-12 | — | — | JP | disclosed |
| JP-S6172773-A | PIPERAZINE DERIVATIVE AND VASODILATOR CONTAINING IT | TERUMO CORP | 1986-04-14 | — | — | JP | disclosed |
| EP-0175331-A1 | Piperazine Derivatives | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1986-03-26 | — | — | EP | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096828-A1 | Cyclic amide compound | CMA1, HRH2, HRH4 | KDM4E 218/4885ALDH1A1 2028/4885HPGD 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.